Armodafinil
- Generic Name
- Armodafinil
- Brand Names
- Nuvigil
- Drug Type
- Small Molecule
- Chemical Formula
- C15H15NO2S
- CAS Number
- 112111-43-0
- Unique Ingredient Identifier
- V63XWA605I
- Background
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patient...
- Indication
用于改善与阻塞性睡眠呼吸暂停（OSA）、发作性睡病或轮班工作障碍（SWD）相关的过度嗜睡的成年患者的清醒度。亦可用于治疗注意缺陷多动障碍、慢性疲劳综合征和重度抑郁症。
- Associated Conditions
- Narcolepsy, Shift-work related sleep disturbance, Somnolence
- Associated Therapies
- -
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
- First Posted Date
- 2010-02-22
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- Cephalon
- Target Recruit Count
- 492
- Registration Number
- NCT01072630
- Locations
- 🇿🇦
Paarl Medical Centre, Paarl, South Africa
🇧🇬Psychiatric clinic for women UMHAT "Dr. Georgi Stranski", Pleven, Bulgaria
🇦🇷B.A. Psychiatric Research Cent, Buenos Aires, Argentina
A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
- First Posted Date
- 2010-02-22
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- Cephalon
- Target Recruit Count
- 433
- Registration Number
- NCT01072929
- Locations
- 🇺🇸
CNS - Comprehensive Neuro Science, Park Ridge, Illinois, United States
🇺🇸Comprehensive Neuroscience, Inc, Atlanta, Georgia, United States
🇺🇸AccelRx Research, Fall River, Massachusetts, United States
Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2010-01-14
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT01048983
Evaluate the Efficacy of Armodafinil for Patients With B-cell Lymphoma and Severe Fatigue
- First Posted Date
- 2010-01-07
- Last Posted Date
- 2013-07-23
- Lead Sponsor
- Washington University School of Medicine
- Registration Number
- NCT01044004
Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors
- Conditions
- Interventions
- First Posted Date
- 2009-12-15
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 54
- Registration Number
- NCT01032200
- Locations
- 🇺🇸
Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
"Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies"
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 20
- Registration Number
- NCT01023672
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Cognitive Behavioral Therapy With or Without Armodafinil in Treating Cancer Survivors With Insomnia and Fatigue After Chemotherapy
- Conditions
- Interventions
- Procedure: Quality-of-life assessmentProcedure: Sleep disorder therapyOther: Questionnaire AdministrationProcedure: Cognitive AssessmentDrug: ArmodafinilOther: PlaceboProcedure: Quality of Life AssessmentProcedure: Fatigue assessment and managementProcedure: Management of TherapyProcedure: Fatifue assessment and managementProcedure: Management of therapy and complications
- First Posted Date
- 2009-11-24
- Last Posted Date
- 2020-04-09
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 226
- Registration Number
- NCT01019187
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Management of Insomnia in Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2018-11-29
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 70
- Registration Number
- NCT01011218
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
Armodafinil in Binge Eating Disorder (BED)
- Conditions
- Interventions
- First Posted Date
- 2009-11-10
- Last Posted Date
- 2015-05-14
- Lead Sponsor
- Lindner Center of HOPE
- Target Recruit Count
- 60
- Registration Number
- NCT01010789
- Locations
- 🇺🇸
Lindner Center of HOPE, Mason, Ohio, United States
Study to Evaluate the Safety, Tolerability, and Efficacy of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury
- First Posted Date
- 2009-09-24
- Last Posted Date
- 2021-12-17
- Lead Sponsor
- Cephalon, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT00983437
- Locations
- 🇺🇸
Teva Investigational Site 8, Houston, Texas, United States
🇺🇸Teva Investigational Site 20, Houston, Texas, United States
🇺🇸Teva Investigational Site 1, Orlando, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.